What’s new in the 2026 EAS guideline on pediatric familial hypercholesterolemia?
Thursday, October 22 at 14:00 BST | 15:00 CEST | 09:00 EDT | 06:00 PDT
Understand the key 2026 updates shaping the diagnosis and management of pediatric familial hypercholesterolemia.
Familial hypercholesterolemia (FH) is a common genetic disorder characterized by lifelong elevated LDL-C and an increased risk of premature atherosclerotic cardiovascular disease (ASCVD). Despite the benefits of early intervention, underdiagnosis and undertreatment remain major challenges, particularly in children.
Published in May 2026, the new European Atherosclerosis Society (EAS) consensus statement introduces important updates to support earlier identification and more effective management of both heterozygous FH (HeFH) and homozygous FH (HoFH).
In this SelectScience® webinar, held in partnership with Devyser, discover what has changed and what the latest recommendations could mean for pediatric FH care.
In this webinar, you will learn:
- How revised diagnostic criteria aim to improve detection of pediatric FH
- Why reducing cumulative LDL-C exposure from childhood is critical
- When earlier lipid-lowering therapy should be considered, including treatment before puberty and, when needed, from age 6
- How LDL-C treatment goals and management algorithms for HeFH and HoFH have evolved
- The latest evidence supporting newer lipid-lowering therapies
- Approaches to improving pediatric screening and transition to adult care
Register now to gain a practical overview of the 2026 EAS recommendations and their implications for earlier diagnosis, treatment, and long-term cardiovascular outcomes in children and adolescents with FH.
Webinar details
- Cost: Free to attend
- Location: Online
- Duration: 60 minutes
Registration is required to secure your place. If you register but can’t attend live, you will receive a link to the on‑demand recording once it becomes available.
Speakers
Who should attend?
- Clinicians
- Lab managers
- Lab directors
- Lab technicians
- Researchers
- Physicians
What will this webinar cover?
Join the webinar to get answers to these questions:
- What are the latest EAS recommendations for identifying pediatric familial hypercholesterolemia?
- Why is earlier diagnosis of FH important for reducing lifelong LDL-C exposure?
- When should lipid-lowering therapy begin in children with HeFH?
- What are the updated LDL-C treatment goals and management approaches for HeFH and HoFH?
- How can screening programs and effective transition to adult care improve patient outcomes?
Links
Related content
Same disease, different testing approaches
Global survey highlights the need for standardized FH genetic testing